Defeating Alzheimer's disease and other dementias: a priority for European science and society

The Lancet Neurology - Tập 15 Số 5 - Trang 455-532 - 2016

Bengt Winblad^1,2, Philippe Amouyel³, Sandrine Andrieu⁴, Clive Ballard⁵, Carol Brayne⁶, Henry Brodaty⁷, Ángel Cedazo-Mı́nguez², Bruno Dubois⁸, David Edvardsson^9,10, Howard Feldman¹¹, Laura Fratiglioni¹², Giovanni B. Frisoni^13,14, Serge Gauthier¹⁵, Jean Georges¹⁶, Caroline Graff^1,2, Khalid Iqbal¹⁷, Frank Jessen^18,19, Gunilla Johansson², Linus Jönsson², Miia Kivipelto^1,12,2, Martín Knapp²⁰, Francesca Mangialasche¹², René J. F. Melis²¹, Agneta Nordberg^1,22, Marcel G. M. Olde Rikkert²¹, Chengxuan Qiu¹², Thomas P. Sakmar^2,23, Philip Scheltens²⁴, Lon S. Schneider²⁵, Reisa A. Sperling²⁶, Lars O. Tjernberg², Gunhild Waldemar²⁷, Anders Wimo², Henrik Zetterberg^28,29

¹Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

²Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden

³Centre Hospitalier Régional Universitaire de Lille, Institut Pasteur de Lille, INSERM U1167 RID-AGE, Unité d'Epidémiologie et de Santé Publique, Labex DISTALZ, Lille, France

⁴Department of Epidemiology and Public Health, Faculty of Medicine, Toulouse University Hospital, Toulouse, France

⁵Wolfson Centre for Age-Related Diseases, King’s College London, London, UK

⁶Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK

⁷Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, University of New South Wales, Sydney, NSW, Australia

⁸Institut de la Mémoire et de la Maladie d'Alzheimer, IM2A, INSERM, Institut du Cerveau et de la Moelle Épinière, UMR-S975, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France

⁹Department of Nursing, Umeå University, Umeå, Sweden

¹⁰School of Nursing and Midwifery, La Trobe University, Melbourne, VIC, Australia

¹¹Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

¹²Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Aging Research Center, Karolinska Institutet, Stockholm, Sweden

¹³Geneva University Hospitals and University of Geneva, Geneva, Switzerland

¹⁴IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

¹⁵McGill Center for Studies in Aging, Alzheimer's Disease Research Unit, and Douglas Mental Health University Institute, Montreal, QC, Canada

¹⁶Alzheimer Europe, Luxembourg City, Luxembourg

¹⁷Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research, Staten Island, NY, USA

¹⁸Department of Psychiatry, University of Cologne, Cologne, Germany

¹⁹German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

²⁰Personal Social Services Research Unit, London School of Economics and Political Science, London, UK

²¹Radboudumc Alzheimer Centre and Department of Geriatric Medicine, Radboud University Medical Center, Nijmegen, Netherlands

²²Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Translational Alzheimer Biology, Karolinska Institutet, Huddinge, Sweden

²³Laboratory of Chemical Biology & Signal Transduction, The Rockefeller University, New York, NY, USA

²⁴Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus, Amsterdam, Netherlands

²⁵Department of Psychiatry and the Behavioral Sciences and Department of Neurology, Keck School of Medicine, Leonard Davis School of Gerontology of the University of Southern California, Los Angeles, CA, USA

²⁶Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

²⁷Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

²⁸Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

²⁹UCL Institute of Neurology, Queen Square, London, UK

Tóm tắt

Từ khóa

Tài liệu tham khảo

1987

Prince, 2015

2012

2015

Wimo, 2013, The worldwide economic impact of dementia 2010, Alzheimers Dement, 9, 1, 10.1016/j.jalz.2012.11.006

Gustavsson, 2011, Cost of disorders of the brain in Europe 2010, Eur Neuropsychopharmacol, 21, 718, 10.1016/j.euroneuro.2011.08.008

Gustavsson, 2011, Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients, Alzheimers Dement, 7, 318, 10.1016/j.jalz.2010.09.001

2014, 2014 Alzheimer's disease facts and figures, Alzheimers Dement, 10, e47, 10.1016/j.jalz.2014.02.001

Prince, 2011

Wimo, 2013, Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry, Int J Geriatr Psychiatry, 28, 1039, 10.1002/gps.3925

Gustavsson, 2010, Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease, Int J Geriatr Psychiatry, 25, 622, 10.1002/gps.2385

Neumann, 1999, Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers, Med Care, 37, 27, 10.1097/00005650-199901000-00005

Jönsson, 2006, Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL, Alzheimer Dis Assoc Disord, 20, 49, 10.1097/01.wad.0000201851.52707.c9

Brown, 2001, Utility values associated with blindness in an adult population, Br J Ophthalmol, 85, 327, 10.1136/bjo.85.3.327

Mulhern, 2013, Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation, Health Technol Assess, 17, v, 10.3310/hta17050

Hausner, 2010, Regional variation on the presentation of Alzheimer's disease patients in memory clinics within Europe: data from the ICTUS study, J Alzheimers Dis, 21, 155, 10.3233/JAD-2010-091489

Chisholm, 2003, Generalized cost-effectiveness analysis for national-level priority-setting in the health sector, Cost Effect Resource Allocation, 1, 8, 10.1186/1478-7547-1-8

Lagergren, 2004, A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC), Aging Clin Exp Res, 16, 158, 10.1007/BF03324546

Gustavsson, 2010, Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study, J Nutr Health Aging, 14, 648, 10.1007/s12603-010-0311-7

Sköldunger, 2013, Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease—a simulation study, Curr Alzheimer Res, 10, 207, 10.2174/1567205011310020011

Stern, 2012, Cognitive reserve in ageing and Alzheimer's disease, Lancet Neurol, 11, 1006, 10.1016/S1474-4422(12)70191-6

Wardlaw, 2013, Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration, Lancet Neurol, 12, 822, 10.1016/S1474-4422(13)70124-8

Bettens, 2013, Genetic insights in Alzheimer's disease, Lancet Neurol, 12, 92, 10.1016/S1474-4422(12)70259-4

Joshi, 2012, Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease, J Neurol, 259, 2182, 10.1007/s00415-012-6481-y

Handels, 2013, Determinants of care costs of patients with dementia or cognitive impairment, Alzheimer Dis Assoc Disord, 27, 30, 10.1097/WAD.0b013e318242da1d

Fratiglioni, 1994, Severity of dementia and institutionalization in the elderly: prevalence data from an urban area in Sweden, Neuroepidemiology, 13, 79, 10.1159/000110363

Helmer, 2006, Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity, Dement Geriatr Cogn Disord, 22, 87, 10.1159/000093459

Ganguli, 2005, Alzheimer disease and mortality: a 15-year epidemiological study, Arch Neurol, 62, 779, 10.1001/archneur.62.5.779

Brookmeyer, 2002, Survival following a diagnosis of Alzheimer disease, Arch Neurol, 59, 1764, 10.1001/archneur.59.11.1764

Larson, 2004, Survival after initial diagnosis of Alzheimer disease, Ann Intern Med, 140, 501, 10.7326/0003-4819-140-7-200404060-00008

Helzner, 2008, Survival in Alzheimer disease: a multiethnic, population-based study of incident cases, Neurology, 71, 1489, 10.1212/01.wnl.0000334278.11022.42

Xie, 2008, Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up, BMJ, 336, 258, 10.1136/bmj.39433.616678.25

Fitzpatrick, 2005, Survival following dementia onset: Alzheimer's disease and vascular dementia, J Neurol Sci, 229-230, 43, 10.1016/j.jns.2004.11.022

Guehne, 2005, Mortality in dementia, Neuroepidemiology, 25, 153, 10.1159/000086680

Helmer, 2001, Mortality with dementia: results from a French prospective community-based cohort, Am J Epidemiol, 154, 642, 10.1093/aje/154.7.642

Todd, 2013, Survival in dementia and predictors of mortality: a review, Int J Geriatr Psychiatry, 28, 1109, 10.1002/gps.3946

Rizzuto, 2012, Dementia after age 75: survival in different severity stages and years of life lost, Curr Alzheimer Res, 9, 795, 10.2174/156720512802455421

Brodaty, 2012, Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia, Int Psychogeriatr, 24, 1034, 10.1017/S1041610211002924

Agüero-Torres, 2002, Dementing disorders in the elderly: evolution of disease severity over 7 years, Alzheimer Dis Assoc Disord, 16, 221, 10.1097/00002093-200210000-00003

Tschanz, 2011, Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study, Am J Geriatr Psychiatry, 19, 532, 10.1097/JGP.0b013e3181faec23

Black, 2002, Cognitive and functional decline in adults aged 75 and older, J Am Geriatr Soc, 50, 1978, 10.1046/j.1532-5415.2002.50609.x

Ishizaki, 2006, Effects of cognitive function on functional decline among community-dwelling non-disabled older Japanese, Arch Gerontol Geriatr, 42, 47, 10.1016/j.archger.2005.06.001

Millán-Calenti, 2012, Cognitive impairment as predictor of functional dependence in an elderly sample, Arch Gerontol Geriatr, 54, 197, 10.1016/j.archger.2011.02.010

Dodge, 2005, Cognitive impairment as a strong predictor of incident disability in specific ADL-IADL tasks among community-dwelling elders: the Azuchi Study, Gerontologist, 45, 222, 10.1093/geront/45.2.222

Artero, 2001, Disability and mild cognitive impairment: a longitudinal population-based study, Int J Geriatr Psychiatry, 16, 1092, 10.1002/gps.477

Blaum, 2002, Low cognitive performance, comorbid disease, and task-specific disability: findings from a nationally representative survey, J Gerontol A Biol Sci Med Sci, 57, M523, 10.1093/gerona/57.8.M523

Mariani, 2008, Influence of comorbidity and cognitive status on instrumental activities of daily living in amnestic mild cognitive impairment: results from the ReGAl project, Int J Geriatr Psychiatry, 23, 523, 10.1002/gps.1932

Schwarzkopf, 2013, Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data, BMC Health Serv Res, 13, 2, 10.1186/1472-6963-13-2

König, 2014, The costs of dementia from the societal perspective: is care provided in the community really cheaper than nursing home care?, J Am Med Dir Assoc, 15, 117, 10.1016/j.jamda.2013.10.003

Wimo, 2010

Chen, 2014, The challenges of dementia care in rural China, Int Psychogeriatr, 26, 1059, 10.1017/S1041610214000854

Brodaty, 2014, Predictors of institutionalization in dementia: a three year longitudinal study, J Alzheimers Dis, 40, 221, 10.3233/JAD-131850

Brayne, 2006, Dementia before death in ageing societies—the promise of prevention and the reality, PLoS Med, 3, e397, 10.1371/journal.pmed.0030397

Matthews, 2009, Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study, PLoS Med, 6, e1000180, 10.1371/journal.pmed.1000180

Neale, 2001, Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over, Int J Epidemiol, 30, 1383, 10.1093/ije/30.6.1383

James, 2014, Contribution of Alzheimer disease to mortality in the United States, Neurology, 82, 1045, 10.1212/WNL.0000000000000240

Jin, 2004, Sensitivity and specificity of dementia coding in two Swedish disease registries, Neurology, 63, 739, 10.1212/01.WNL.0000134604.48018.97

Marengoni, 2011, Aging with multimorbidity: a systematic review of the literature, Ageing Res Rev, 10, 430, 10.1016/j.arr.2011.03.003

Weuve, 2014, Deaths in the United States among persons with Alzheimer's disease (2010–2050), Alzheimers Dement, 10, e40, 10.1016/j.jalz.2014.01.004

Thies, 2013, 2013 Alzheimer's disease facts and figures, Alzheimers Dement, 9, 208, 10.1016/j.jalz.2013.02.003

Murray, 2013, UK health performance: findings of the Global Burden of Disease Study 2010, Lancet, 381, 997, 10.1016/S0140-6736(13)60355-4

Qiu, 2013, Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden, Neurology, 80, 1888, 10.1212/WNL.0b013e318292a2f9

Prince, 2012, Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study, Lancet, 380, 50, 10.1016/S0140-6736(12)60399-7

Llibre Rodriguez, 2008, Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey, Lancet, 372, 464, 10.1016/S0140-6736(08)61002-8

Kalaria, 2008, Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors, Lancet Neurol, 7, 812, 10.1016/S1474-4422(08)70169-8

Prince, 2013, The global prevalence of dementia: a systematic review and metaanalysis, Alzheimers Dement, 9, 63, 10.1016/j.jalz.2012.11.007

Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0

Russ, 2012, Geographical variation in dementia: systematic review with meta-analysis, Int J Epidemiol, 41, 1012, 10.1093/ije/dys103

Wu, 2013, Prevalence studies of dementia in mainland China, Hong Kong and Taiwan: a systematic review and meta-analysis, PLoS ONE, 8, e66252, 10.1371/journal.pone.0066252

Fratiglioni, 2013, Epidemiology of dementia, 389

Langa, 2008, Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity?, Alzheimers Dement, 4, 134, 10.1016/j.jalz.2008.01.001

Hall, 2009, Prevalence rates for dementia and Alzheimer's disease in African Americans: 1992 versus 2001, Alzheimers Dement, 5, 227, 10.1016/j.jalz.2009.01.026

Hebert, 2010, Change in risk of Alzheimer disease over time, Neurology, 75, 786, 10.1212/WNL.0b013e3181f0754f

Rocca, 2011, Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States, Alzheimers Dement, 7, 80, 10.1016/j.jalz.2010.11.002

Gao, 2015, Dementia incidence declined in African-Americans but not in Yoruba, Alzheimers Dement

Satizabal, 2016, Incidence of dementia over three decades in the Framingham Heart Study, N Engl J Med, 374, 523, 10.1056/NEJMoa1504327

Lobo, 2007, Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP Project, Acta Psychiatr Scand, 116, 299, 10.1111/j.1600-0447.2007.01006.x

Schrijvers, 2012, Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study, Neurology, 78, 1456, 10.1212/WNL.0b013e3182553be6

Wiberg, 2013, Secular trends in the prevalence of dementia and depression in Swedish septuagenarians 1976-2006, Psychol Med, 43, 2627, 10.1017/S0033291713000299

Matthews, 2013, A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II, Lancet, 382, 1405, 10.1016/S0140-6736(13)61570-6

Li, 2007, Is the dementia rate increasing in Beijing? Prevalence and incidence of dementia 10 years later in an urban elderly population, Acta Psychiatr Scand, 115, 73, 10.1111/j.1600-0447.2006.00859.x

Yu, 2012, Trends in prevalence and mortality of dementia in elderly Hong Kong population: projections, disease burden, and implications for long-term care, Int J Alzheimers Dis, 2012, 406852

Chan, 2013, Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis, Lancet, 381, 2016, 10.1016/S0140-6736(13)60221-4

Wu, 2014, Period, birth cohort and prevalence of dementia in mainland China, Hong Kong and Taiwan: a meta-analysis, Int J Geriatr Psychiatry, 29, 1212, 10.1002/gps.4148

Sekita, 2010, Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: the Hisayama Study, Acta Psychiatr Scand, 122, 319, 10.1111/j.1600-0447.2010.01587.x

Dodge, 2012, Trends in the prevalence of dementia in Japan, Int J Alzheimers Dis, 2012, 956354

Larson, 2013, New insights into the dementia epidemic, N Engl J Med, 369, 2275, 10.1056/NEJMp1311405

Whalley, 2012, Spatial distribution and secular trends in the epidemiology of Alzheimer's disease, Neuroimaging Clin N Am, 22, 1, 10.1016/j.nic.2011.11.002

Wu, 2016, Dementia in western Europe: epidemiological evidence and implications for policy making, Lancet Neurol, 15, 116, 10.1016/S1474-4422(15)00092-7

Manton, 2005, Declining prevalence of dementia in the U.S. elderly population, Adv Gerontol, 16, 30

Sheffield, 2011, Changes in the prevalence of cognitive impairment among older Americans, 1993-2004: overall trends and differences by race/ethnicity, Am J Epidemiol, 174, 274, 10.1093/aje/kwr074

Kiejna, 2011, Epidemiological studies of cognitive impairment and dementia across Eastern and Middle European countries (epidemiology of dementia in Eastern and Middle European Countries), Int J Geriatr Psychiatry, 26, 111, 10.1002/gps.2511

Misiak, 2013, European studies on the prevalence of dementia in the elderly: time for a step towards a methodological consensus, Int J Geriatr Psychiatry, 28, 1211, 10.1002/gps.3948

Jia, 2014, The prevalence of dementia in urban and rural areas of China, Alzheimers Dement, 10, 1, 10.1016/j.jalz.2013.01.012

Prince, 2013, Dementia in China: east-west collaboration bears fruit, Lancet, 381, 1967, 10.1016/S0140-6736(13)60770-9

Yang, 2013, Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010, Lancet, 381, 1987, 10.1016/S0140-6736(13)61097-1

Heuschmann, 2008, Ethnic group disparities in 10-year trends in stroke incidence and vascular risk factors: the South London Stroke Register (SLSR), Stroke, 39, 2204, 10.1161/STROKEAHA.107.507285

Börjesson-Hanson, 2004, The prevalence of dementia in 95 year olds, Neurology, 63, 2436, 10.1212/01.WNL.0000147260.52841.27

Corrada, 2008, Prevalence of dementia after age 90: results from the 90+ study, Neurology, 71, 337, 10.1212/01.wnl.0000310773.65918.cd

Balasubramanian, 2012, Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia, Neurology, 79, 915, 10.1212/WNL.0b013e318266fc77

Corrada, 2012, A population-based clinicopathological study in the oldest-old: the 90+ study, Curr Alzheimer Res, 9, 709, 10.2174/156720512801322537

Middleton, 2011, Neuropathologic features associated with Alzheimer disease diagnosis: age matters, Neurology, 77, 1737, 10.1212/WNL.0b013e318236f0cf

Savva, 2009, Age, neuropathology, and dementia, N Engl J Med, 360, 2302, 10.1056/NEJMoa0806142

Ferrari, 2013, How can elderly apolipoprotein E ɛ4 carriers remain free from dementia?, Neurobiol Aging, 34, 13, 10.1016/j.neurobiolaging.2012.03.003

Barnes, 2011, The projected effect of risk factor reduction on Alzheimer's disease prevalence, Lancet Neurol, 10, 819, 10.1016/S1474-4422(11)70072-2

Qiu, 2010, Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention, J Alzheimers Dis, 20, 689, 10.3233/JAD-2010-091663

Barnes, 2010, Secondhand smoke, vascular disease, and dementia incidence: findings from the cardiovascular health cognition study, Am J Epidemiol, 171, 292, 10.1093/aje/kwp376

Chen, 2012, Association of environmental tobacco smoke with dementia and Alzheimer's disease among never smokers, Alzheimers Dement, 8, 590, 10.1016/j.jalz.2011.09.231

Lu, 2009, Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis, PLoS ONE, 4, e4144, 10.1371/journal.pone.0004144

Profenno, 2010, Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders, Biol Psychiatry, 67, 505, 10.1016/j.biopsych.2009.02.013

Anstey, 2009, Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies, Am J Geriatr Psychiatry, 17, 542, 10.1097/JGP.0b013e3181a2fd07

Ilomaki, 2015, Alcohol consumption, dementia and cognitive deline: An overview of systematic reviews, Curr Clin Pharmacol, 10, 204, 10.2174/157488471003150820145539

Blondell, 2014, Does physical activity prevent cognitive decline and dementia?: A systematic review and meta-analysis of longitudinal studies, BMC Public Health, 14, 510, 10.1186/1471-2458-14-510

Qiu, 2012, Preventing Alzheimer's disease by targeting vascular risk factors: hope and gap, J Alzheimers Dis, 32, 721, 10.3233/JAD-2012-120922

Stewart, 2007, Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study, Arch Neurol, 64, 103, 10.1001/archneur.64.1.103

Stewart, 2005, A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study, Arch Neurol, 62, 55, 10.1001/archneur.62.1.55

Stewart, 2009, Change in blood pressure and incident dementia: a 32-year prospective study, Hypertension, 54, 233, 10.1161/HYPERTENSIONAHA.109.128744

Joas, 2012, Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years, Hypertension, 59, 796, 10.1161/HYPERTENSIONAHA.111.182204

Barnes, 2009, Predicting risk of dementia in older adults: The late-life dementia risk index, Neurology, 73, 173, 10.1212/WNL.0b013e3181a81636

Reitz, 2010, A summary risk score for the prediction of Alzheimer disease in elderly persons, Arch Neurol, 67, 835, 10.1001/archneurol.2010.136

Anstey, 2014, A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: the ANU-ADRI, PLoS ONE, 9, e86141, 10.1371/journal.pone.0086141

Exalto, 2014, Midlife risk score for the prediction of dementia four decades later, Alzheimers Dement, 10, 562, 10.1016/j.jalz.2013.05.1772

Kivipelto, 2006, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study, Lancet Neurol, 5, 735, 10.1016/S1474-4422(06)70537-3

Meng, 2012, Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses, PLoS ONE, 7, e38268, 10.1371/journal.pone.0038268

Barnes, 2012, Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia, Arch Gen Psychiatry, 69, 493, 10.1001/archgenpsychiatry.2011.1481

Diniz, 2013, Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies, Br J Psychiatry, 202, 329, 10.1192/bjp.bp.112.118307

Rodrigue, 2013, Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects, JAMA Neurol, 70, 600, 10.1001/jamaneurol.2013.1342

Qiu, 2014, Diabetes, markers of brain pathology and cognitive function: the Age, Gene/Environment Susceptibility-Reykjavik Study, Ann Neurol, 75, 138, 10.1002/ana.24063

Roberts, 2014, Association of type 2 diabetes with brain atrophy and cognitive impairment, Neurology, 82, 1132, 10.1212/WNL.0000000000000269

Garcia-Alloza, 2011, Cerebrovascular lesions induce transient β-amyloid deposition, Brain, 134, 3697, 10.1093/brain/awr300

Casserly, 2004, Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins, Lancet, 363, 1139, 10.1016/S0140-6736(04)15900-X

Pantoni, 2010, Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges, Lancet Neurol, 9, 689, 10.1016/S1474-4422(10)70104-6

Toledo, 2013, Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre, Brain, 136, 2697, 10.1093/brain/awt188

Strozyk, 2010, Contribution of vascular pathology to the clinical expression of dementia, Neurobiol Aging, 31, 1710, 10.1016/j.neurobiolaging.2008.09.011

Schneider, 2007, Mixed brain pathologies account for most dementia cases in community-dwelling older persons, Neurology, 69, 2197, 10.1212/01.wnl.0000271090.28148.24

Viswanathan, 2009, Vascular risk factors and dementia: how to move forward?, Neurology, 72, 368, 10.1212/01.wnl.0000341271.90478.8e

Stephan, 2012, Neuropathological profile of mild cognitive impairment from a population perspective, Alzheimer Dis Assoc Disord, 26, 205, 10.1097/WAD.0b013e31822fc24d

Bennett, 2006, The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study, Lancet Neurol, 5, 406, 10.1016/S1474-4422(06)70417-3

Brayne, 2010, Education, the brain and dementia: neuroprotection or compensation?, Brain, 133, 2210, 10.1093/brain/awq185

Bennett, 2014, Cognitive and social lifestyle: links with neuropathology and cognition in late life, Acta Neuropathol, 127, 137, 10.1007/s00401-013-1226-2

Daviglus, 2010, National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline, Ann Intern Med, 153, 176, 10.7326/0003-4819-153-3-201008030-00260

Coley, 2008, Dementia prevention: methodological explanations for inconsistent results, Epidemiol Rev, 30, 35, 10.1093/epirev/mxn010

Daviglus, 2011, Risk factors and preventive interventions for Alzheimer disease: state of the science, Arch Neurol, 68, 1185, 10.1001/archneurol.2011.100

Whalley, 2006, A life-course approach to the aetiology of late-onset dementias, Lancet Neurol, 5, 87, 10.1016/S1474-4422(05)70286-6

Launer, 2010, Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study, Hypertension, 55, 1352, 10.1161/HYPERTENSIONAHA.109.147389

Brayne, 2007, The elephant in the room—healthy brains in later life, epidemiology and public health, Nat Rev Neurosci, 8, 233, 10.1038/nrn2091

Richard, 2012, Methodological challenges in designing dementia prevention trials—the European Dementia Prevention Initiative (EDPI), J Neurol Sci, 322, 64, 10.1016/j.jns.2012.06.012

Brodaty, 2011, The world of dementia beyond 2020, J Am Geriatr Soc, 59, 923, 10.1111/j.1532-5415.2011.03365.x

Godbolt, 2014, Systematic review of the risk of dementia and chronic cognitive impairment after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis, Arch Phys Med Rehabil, 95, S245, 10.1016/j.apmr.2013.06.036

Mayeux, 2012, Epidemiology of Alzheimer disease, Cold Spring Harb Perspect Med, 2, a006239, 10.1101/cshperspect.a006239

Wang, 2012, Population based study on patients with traumatic brain injury suggests increased risk of dementia, J Neurol Neurosurg Psychiatry, 83, 1080, 10.1136/jnnp-2012-302633

Barnes, 2014, Traumatic brain injury and risk of dementia in older veterans, Neurology, 83, 312, 10.1212/WNL.0000000000000616

Nordström, 2014, Traumatic brain injury and young onset dementia: a nationwide cohort study, Ann Neurol, 75, 374, 10.1002/ana.24101

Roberts, 1991, β A4 amyloid protein deposition in brain after head trauma, Lancet, 338, 1422, 10.1016/0140-6736(91)92724-G

Johnson, 2012, Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans, Brain Pathol, 22, 142, 10.1111/j.1750-3639.2011.00513.x

Magnoni, 2012, Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury, Brain, 135, 1268, 10.1093/brain/awr286

Marklund, 2014, Monitoring of β-amyloid dynamics after human traumatic brain injury, J Neurotrauma, 31, 42, 10.1089/neu.2013.2964

Marklund, 2009, Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury, J Neurosurg, 110, 1227, 10.3171/2008.9.JNS08584

Mielke, 2014, Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study, Neurology, 82, 70, 10.1212/01.wnl.0000438229.56094.54

Blennow, 2012, The neuropathology and neurobiology of traumatic brain injury, Neuron, 76, 886, 10.1016/j.neuron.2012.11.021

Singh, 2014, Relationship of collegiate football experience and concussion with hippocampal volume and cognitive outcomes, JAMA, 311, 1883, 10.1001/jama.2014.3313

Stein, 2014, Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel, Alzheimers Res Ther, 6, 4, 10.1186/alzrt234

Zetterberg, 2013, Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood, Nat Rev Neurol, 9, 201, 10.1038/nrneurol.2013.9

Brayne, 2011, A European perspective on population studies of dementia, Alzheimers Dement, 7, 3, 10.1016/j.jalz.2010.12.003

Nordström, 2013, Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study, JAMA Intern Med, 173, 1612, 10.1001/jamainternmed.2013.9079

Lambert, 2014, Estimating the burden of early onset dementia; systematic review of disease prevalence, Eur J Neurol, 21, 563, 10.1111/ene.12325

Norton, 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, Lancet Neurol, 13, 788, 10.1016/S1474-4422(14)70136-X

Brookmeyer, 1998, Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset, Am J Public Health, 88, 1337, 10.2105/AJPH.88.9.1337

Jorm, 2005, Projections of future numbers of dementia cases in Australia with and without prevention, Aust N Z J Psychiatry, 39, 959, 10.1080/j.1440-1614.2005.01713.x

Solomon, 2014, Advances in the prevention of Alzheimer's disease and dementia, J Intern Med, 275, 229, 10.1111/joim.12178

Ng, 2014, Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet, 384, 766, 10.1016/S0140-6736(14)60460-8

Shumaker, 2004, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA, 291, 2947, 10.1001/jama.291.24.2947

Shumaker, 2003, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2651, 10.1001/jama.289.20.2651

Martin, 2008, Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib, Arch Neurol, 65, 896, 10.1001/archneur.2008.65.7.nct70006

Peters, 2008, Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial, Lancet Neurol, 7, 683, 10.1016/S1474-4422(08)70143-1

Kryscio, 2014, Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point, JAMA Neurol, 71, 947, 10.1001/jamaneurol.2014.1120

Kivipelto, 2013, The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress, Alzheimers Dement, 9, 657, 10.1016/j.jalz.2012.09.012

Carrié, 2012, Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial), J Nutr Health Aging, 16, 355, 10.1007/s12603-012-0046-8

Richard, 2009, Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress, Alzheimer Dis Assoc Disord, 23, 198, 10.1097/WAD.0b013e31819783a4

Ngandu, 2015, A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, Lancet, 385, 2255, 10.1016/S0140-6736(15)60461-5

Schneider, 2014, Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014, J Intern Med, 275, 251, 10.1111/joim.12191

Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N Engl J Med, 367, 795, 10.1056/NEJMoa1202753

Lopera, 1997, Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation, JAMA, 277, 793, 10.1001/jama.1997.03540340027028

Miller, 2012, Alzheimer's research. Stopping Alzheimer's before it starts, Science, 337, 790, 10.1126/science.337.6096.790

Smith, 2014, Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts, J Alzheimers Dis, 38, 699

Zhang, 2011, Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting, J Alzheimers Dis, 26, 735, 10.3233/JAD-2011-110065

Gatz, 2006, Role of genes and environments for explaining Alzheimer disease, Arch Gen Psychiatry, 63, 168, 10.1001/archpsyc.63.2.168

Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature, 349, 704, 10.1038/349704a0

Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375, 754, 10.1038/375754a0

Levy-Lahad, 1995, Candidate gene for the chromosome 1 familial Alzheimer's disease locus, Science, 269, 973, 10.1126/science.7638622

Strittmatter, 1993, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc Natl Acad Sci USA, 90, 8098, 10.1073/pnas.90.17.8098

Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443

Farrer, 1997, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis, JAMA, 278, 1349, 10.1001/jama.1997.03550160069041

Bertram, 2007, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database, Nat Genet, 39, 17, 10.1038/ng1934

Baltimore, 2001, Our genome unveiled, Nature, 409, 814, 10.1038/35057267

Pennisi, 2007, Breakthrough of the year. Human genetic variation, Science, 318, 1842, 10.1126/science.318.5858.1842

McCarthy, 2008, Genome-wide association studies for complex traits: consensus, uncertainty and challenges, Nat Rev Genet, 9, 356, 10.1038/nrg2344

Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nat Genet, 41, 1094, 10.1038/ng.439

Harold, 2009, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nat Genet, 41, 1088, 10.1038/ng.440

Seshadri, 2010, Genome-wide analysis of genetic loci associated with Alzheimer disease, JAMA, 303, 1832, 10.1001/jama.2010.574

Hollingworth, 2011, Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease, Nat Genet, 43, 429, 10.1038/ng.803

Naj, 2011, Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease, Nat Genet, 43, 436, 10.1038/ng.801

Lambert, 2013, Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease, Nat Genet, 45, 1452, 10.1038/ng.2802

Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994

Pottier, 2012, High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease, Mol Psychiatry, 17, 875, 10.1038/mp.2012.15

Dallongeville, 1992, Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis, J Lipid Res, 33, 447, 10.1016/S0022-2275(20)41611-6

Luc, 1994, Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study, Arterioscler Thromb, 14, 1412, 10.1161/01.ATV.14.9.1412

Chartier-Harlin, 1994, Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region, Hum Mol Genet, 3, 569, 10.1093/hmg/3.4.569

Genin, 2011, APOE and Alzheimer disease: a major gene with semi-dominant inheritance, Mol Psychiatry, 16, 903, 10.1038/mp.2011.52

Chapuis, 2013, Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology, Mol Psychiatry, 18, 1225, 10.1038/mp.2013.1

Paloneva, 2002, Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype, Am J Hum Genet, 71, 656, 10.1086/342259

Guerreiro, 2013, TREM2 variants in Alzheimer's disease, N Engl J Med, 368, 117, 10.1056/NEJMoa1211851

Jonsson, 2013, Variant of TREM2 associated with the risk of Alzheimer's disease, N Engl J Med, 368, 107, 10.1056/NEJMoa1211103

Cruchaga, 2014, Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease, Nature, 505, 550, 10.1038/nature12825

Lambert, 2015, PLD3 and sporadic Alzheimer's disease risk, Nature, 520, E1, 10.1038/nature14036

Jonsson, 2012, A mutation in APP protects against Alzheimer's disease and age-related cognitive decline, Nature, 488, 96, 10.1038/nature11283

Tomiyama, 2008, A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia, Ann Neurol, 63, 377, 10.1002/ana.21321

Di Fede, 2009, A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis, Science, 323, 1473, 10.1126/science.1168979

Ringman, 2005, What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review, J Geriatr Psychiatry Neurol, 18, 228, 10.1177/0891988705281878

Schöll, 2011, Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation, Neurobiol Aging, 32, 1388, 10.1016/j.neurobiolaging.2009.08.016

Casanova, 2016, Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals, Alzheimers Dement, 10.1016/j.jalz.2015.12.008

Rodriguez-Vieitez, 2016, Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease, Brain, 10.1093/brain/awv404

Morris, 2012, Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network, Clin Investig (Lond), 2, 975, 10.4155/cli.12.93

Amieva, 2008, Prodromal Alzheimer's disease: successive emergence of the clinical symptoms, Ann Neurol, 64, 492, 10.1002/ana.21509

Wang, 2013, Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy, Ageing Res Rev, 12, 1024, 10.1016/j.arr.2013.05.003

Goldman, 2011, Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors, Genet Med, 13, 597, 10.1097/GIM.0b013e31821d69b8

Harms, 2013, C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease, JAMA Neurol, 70, 736, 10.1001/2013.jamaneurol.537

Brunnström, 2009, Clinicopathological concordance in dementia diagnostics, Am J Geriatr Psychiatry, 17, 664, 10.1097/JGP.0b013e3181a6516e

Wright, 2010, Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how?, Hum Genet, 127, 125, 10.1007/s00439-009-0767-x

Roberts, 2011, Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics, Clin Genet, 80, 407, 10.1111/j.1399-0004.2011.01739.x

Bentham, 2005, Services for younger people with dementia, Psychiatry, 4, 100, 10.1383/psyt.4.2.100.59105

McMurtray, 2006, Early-onset dementia: frequency and causes compared to late-onset dementia, Dement Geriatr Cogn Disord, 21, 59, 10.1159/000089546

Panegyres, 2007, Course and causes of suspected dementia in young adults: a longitudinal study, Am J Alzheimers Dis Other Demen, 22, 48, 10.1177/1533317506295887

van der Zee, 2013, A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats, Hum Mutat, 34, 363, 10.1002/humu.22244

Viswanathan, 2011, Cerebral amyloid angiopathy in the elderly, Ann Neurol, 70, 871, 10.1002/ana.22516

Hernández, 2007, Tauopathies, Cell Mol Life Sci, 64, 2219, 10.1007/s00018-007-7220-x

Shioi, 2007, FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta, J Neurochem, 101, 674, 10.1111/j.1471-4159.2006.04391.x

Shepherd, 2009, Variations in the neuropathology of familial Alzheimer's disease, Acta Neuropathol, 118, 37, 10.1007/s00401-009-0521-4

Sandebring, 2013, The pathogenic Aβ43 is enriched in familial and sporadic Alzheimer disease, PLoS ONE, 8, e55847, 10.1371/journal.pone.0055847

Lorenzo, 1994, Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red, Proc Natl Acad Sci USA, 91, 12243, 10.1073/pnas.91.25.12243

Lambert, 1998, Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins, Proc Natl Acad Sci USA, 95, 6448, 10.1073/pnas.95.11.6448

Cleary, 2005, Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function, Nat Neurosci, 8, 79, 10.1038/nn1372

Shankar, 2008, Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory, Nat Med, 14, 837, 10.1038/nm1782

Chételat, 2013, Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease, Neuroimage Clin, 2, 356, 10.1016/j.nicl.2013.02.006

Zou, 2002, A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage, J Neurosci, 22, 4833, 10.1523/JNEUROSCI.22-12-04833.2002

Soscia, 2010, The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide, PLoS ONE, 5, e9505, 10.1371/journal.pone.0009505

Vestling, 1999, Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases, Biochim Biophys Acta, 1453, 341, 10.1016/S0925-4439(99)00003-4

Cedazo-Mínguez, 2001, Apolipoprotein E isoform-specific disruption of phosphoinositide hydrolysis: protection by estrogen and glutathione, FEBS Lett, 504, 45, 10.1016/S0014-5793(01)02761-2

Tabaton, 2010, Signaling effect of amyloid-beta(42) on the processing of AbetaPP, Exp Neurol, 221, 18, 10.1016/j.expneurol.2009.09.002

Yao, 2002, Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity, FASEB J, 16, 1677, 10.1096/fj.02-0285fje

Gersbacher, 2010, Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit, Mol Neurodegener, 5, 61, 10.1186/1750-1326-5-61

Hu, 2006, Bace1 modulates myelination in the central and peripheral nervous system, Nat Neurosci, 9, 1520, 10.1038/nn1797

Willem, 2006, Control of peripheral nerve myelination by the beta-secretase BACE1, Science, 314, 664, 10.1126/science.1132341

Jurisch-Yaksi, 2013, A fast growing spectrum of biological functions of γ-secretase in development and disease, Biochim Biophys Acta, 1828, 2815, 10.1016/j.bbamem.2013.04.016

Barthet, 2012, Cellular mechanisms of γ-secretase substrate selection, processing and toxicity, Prog Neurobiol, 98, 166, 10.1016/j.pneurobio.2012.05.006

Cowburn, 2007, Presenilin-mediated signal transduction, Physiol Behav, 92, 93, 10.1016/j.physbeh.2007.05.053

Pardossi-Piquard, 2012, The physiology of the β-amyloid precursor protein intracellular domain AICD, J Neurochem, 120, 109, 10.1111/j.1471-4159.2011.07475.x

Rice, 2012, Pancortins interact with amyloid precursor protein and modulate cortical cell migration, Development, 139, 3986, 10.1242/dev.082909

Aydin, 2012, Functions of the APP gene family in the nervous system: insights from mouse models, Exp Brain Res, 217, 423, 10.1007/s00221-011-2861-2

Octave, 2013, From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein, J Neurochem, 126, 183, 10.1111/jnc.12239

Duce, 2010, Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease, Cell, 142, 857, 10.1016/j.cell.2010.08.014

Luo, 2003, BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time, Neurobiol Dis, 14, 81, 10.1016/S0969-9961(03)00104-9

Wisniewski, 2015, Immunotherapeutic approaches for Alzheimer's disease, Neuron, 85, 1162, 10.1016/j.neuron.2014.12.064

Iqbal, 2006, Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective, J Alzheimers Dis, 9, 219, 10.3233/JAD-2006-9S325

Goedert, 2005, Mutations causing neurodegenerative tauopathies, Biochim Biophys Acta, 1739, 240, 10.1016/j.bbadis.2004.08.007

Ebneth, 1998, Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease, J Cell Biol, 143, 777, 10.1083/jcb.143.3.777

Grundke-Iqbal, 1986, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA, 83, 4913, 10.1073/pnas.83.13.4913

Alonso, 1994, Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease, Proc Natl Acad Sci USA, 91, 5562, 10.1073/pnas.91.12.5562

Schneider, 2008, Tau-based treatment strategies in neurodegenerative diseases, Neurotherapeutics, 5, 443, 10.1016/j.nurt.2008.05.006

Medina, 2010, Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease, Curr Pharm Des, 16, 2790, 10.2174/138161210793176581

Medina, 2014, New perspectives on the role of tau in Alzheimer's disease. Implications for therapy, Biochem Pharmacol, 88, 540, 10.1016/j.bcp.2014.01.013

Corcoran, 2010, Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model, J Clin Neurosci, 17, 1025, 10.1016/j.jocn.2010.04.020

Matsuoka, 2008, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease, J Pharmacol Exp Ther, 325, 146, 10.1124/jpet.107.130526

Morimoto, 2013, A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment, Dement Geriatr Cogn Disord, 35, 325, 10.1159/000348347

Krafts, 2012, From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy, Parasitol Res, 111, 1, 10.1007/s00436-012-2886-x

Sontag, 2012, Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models, J Neurosci, 32, 11109, 10.1523/JNEUROSCI.0895-12.2012

Panza, 2012, Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies, Immunotherapy, 4, 213, 10.2217/imt.11.170

Bolognin, 2012, An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide, Acta Neuropathol, 123, 133, 10.1007/s00401-011-0908-x

Iqbal, 2013, Animal models of the sporadic form of Alzheimer's disease: focus on the disease and not just the lesions, J Alzheimers Dis, 37, 469, 10.3233/JAD-130827

Saito, 2014, Single App knock-in mouse models of Alzheimer's disease, Nat Neurosci, 17, 661, 10.1038/nn.3697

Franco, 2014, Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?, Front Pharmacol, 5, 146, 10.3389/fphar.2014.00146

Imtiaz, 2014, Future directions in Alzheimer's disease from risk factors to prevention, Biochem Pharmacol, 88, 661, 10.1016/j.bcp.2014.01.003

Shively, 2012, Dementia resulting from traumatic brain injury: what is the pathology?, Arch Neurol, 69, 1245, 10.1001/archneurol.2011.3747

Zhang, 2010, Pathological role of hypoxia in Alzheimer's disease, Exp Neurol, 223, 299, 10.1016/j.expneurol.2009.07.033

Ferreira, 2014, Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease, Alzheimers Dement, 10, S76, 10.1016/j.jalz.2013.12.010

Arif, 2014, Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam, Proc Natl Acad Sci USA, 111, 1144, 10.1073/pnas.1322614111

Gong, 2006, Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation, J Alzheimers Dis, 9, 1, 10.3233/JAD-2006-9101

Hardy, 2014, Pathways to Alzheimer's disease, J Intern Med, 275, 296, 10.1111/joim.12192

Schmechel, 1993, Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc Natl Acad Sci USA, 90, 9649, 10.1073/pnas.90.20.9649

Cedazo-Mínguez, 2001, Beta-VLDL protects against A beta(1-42) and apoE toxicity in human SH-SY5Y neuroblastoma cells, Neuroreport, 12, 201, 10.1097/00001756-200102120-00006

Manelli, 2007, Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation, Neurobiol Aging, 28, 1139, 10.1016/j.neurobiolaging.2006.05.024

Bales, 1999, Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease, Proc Natl Acad Sci USA, 96, 15233, 10.1073/pnas.96.26.15233

LaDu, 1994, Isoform-specific binding of apolipoprotein E to beta-amyloid, J Biol Chem, 269, 23403, 10.1016/S0021-9258(17)31529-6

Björkhem, 2009, Oxysterols and neurodegenerative diseases, Mol Aspects Med, 30, 171, 10.1016/j.mam.2009.02.001

Shen, 2013, What does complement do in Alzheimer's disease? Old molecules with new insights, Transl Neurodegener, 2, 21, 10.1186/2047-9158-2-21

Wilcock, 2013, Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis, J Neuroinflammation, 10, 84, 10.1186/1742-2094-10-84

Terai, 1997, Neurons express proteins of the classical complement pathway in Alzheimer disease, Brain Res, 769, 385, 10.1016/S0006-8993(97)00849-4

Hazrati, 2012, Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism, Neurobiol Aging, 33, e5, 10.1016/j.neurobiolaging.2012.07.001

Rogers, 1992, Complement activation by beta-amyloid in Alzheimer disease, Proc Natl Acad Sci USA, 89, 10016, 10.1073/pnas.89.21.10016

Jiang, 2013, TREM2 in Alzheimer's disease, Mol Neurobiol, 48, 180, 10.1007/s12035-013-8424-8

Kleinberger, 2014, TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis, Sci Transl Med, 6, 243ra86, 10.1126/scitranslmed.3009093

Atagi, 2015, Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2), J Biol Chem, 290, 26043, 10.1074/jbc.M115.679043

Rogaeva, 2007, The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease, Nat Genet, 39, 168, 10.1038/ng1943

Holmes, 2013, Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds, Proc Natl Acad Sci USA, 110, E3138, 10.1073/pnas.1301440110

Goedert, 2015, NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein, Science, 349, 1255555, 10.1126/science.1255555

Beekes, 2014, Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?, Acta Neuropathol, 128, 463, 10.1007/s00401-014-1324-9

Jaunmuktane, 2015, Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy, Nature, 525, 247, 10.1038/nature15369

Erlangsen, 2008, Hospital-diagnosed dementia and suicide: a longitudinal study using prospective, nationwide register data, Am J Geriatr Psychiatry, 16, 220, 10.1097/01.JGP.0000302930.75387.7e

Mormont, 2014, Symptoms of depression and anxiety after the disclosure of the diagnosis of Alzheimer disease, J Geriatr Psychiatry Neurol, 27, 231, 10.1177/0891988714532021

1992

2013

Knopman, 2001, Practice parameter: diagnosis of dementia (an evidence-based review), Neurology, 56, 1143, 10.1212/WNL.56.9.1143

Gaugler, 2013, Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence, Am J Alzheimers Dis Other Demen, 28, 337, 10.1177/1533317513488910

Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 270, 10.1016/j.jalz.2011.03.008

Sperling, 2011, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 280, 10.1016/j.jalz.2011.03.003

McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005

Dubois, 2010, Revising the definition of Alzheimer's disease: a new lexicon, Lancet Neurol, 9, 1118, 10.1016/S1474-4422(10)70223-4

Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3

Dubois, 2014, Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, 13, 614, 10.1016/S1474-4422(14)70090-0

Jessen, 2014, Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease, Eur Arch Psychiatry Clin Neurosci, 264, S3, 10.1007/s00406-014-0539-z

Jessen, 2010, Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment, Arch Gen Psychiatry, 67, 414, 10.1001/archgenpsychiatry.2010.30

Reisberg, 2010, Outcome over seven years of healthy adults with and without subjective cognitive impairment, Alzheimers Dement, 6, 11, 10.1016/j.jalz.2009.10.002

Jessen, 2011, Prediction of dementia in primary care patients, PLoS ONE, 6, e16852, 10.1371/journal.pone.0016852

Visser, 2009, Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, Lancet Neurol, 8, 619, 10.1016/S1474-4422(09)70139-5

Scheef, 2012, Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment, Neurology, 79, 1332, 10.1212/WNL.0b013e31826c1a8d

Amariglio, 2012, Subjective cognitive complaints and amyloid burden in cognitively normal older individuals, Neuropsychologia, 50, 2880, 10.1016/j.neuropsychologia.2012.08.011

van Harten, 2013, Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints, Alzheimers Dement, 9, 481, 10.1016/j.jalz.2012.08.004

Jessen, 2014, A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease, Alzheimers Dement, 10, 844, 10.1016/j.jalz.2014.01.001

Sikkes, 2012, A new informant-based questionnaire for instrumental activities of daily living in dementia, Alzheimers Dement, 8, 536, 10.1016/j.jalz.2011.08.006

Sikkes, 2013, Validation of the Amsterdam IADL Questionnaire©, a new tool to measure instrumental activities of daily living in dementia, Neuroepidemiology, 41, 35, 10.1159/000346277

Rockwood, 2006, Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial, CMAJ, 174, 1099, 10.1503/cmaj.051432

Vogel, 2012, Proxy-rated quality of life in Alzheimer's disease: a three-year longitudinal study, Int Psychogeriatr, 24, 82, 10.1017/S1041610211001128

Schölzel-Dorenbos, 2012, Validation study of the prototype of a disease-specific index measure for health-related quality of life in dementia, Health Qual Life Outcomes, 10, 118, 10.1186/1477-7525-10-118

Perales, 2013, Health-related quality-of-life instruments for Alzheimer's disease and mixed dementia, Int Psychogeriatr, 25, 691, 10.1017/S1041610212002293

Hyman, 1997, Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease, J Neuropathol Exp Neurol, 56, 1095, 10.1097/00005072-199710000-00002

Kovacs, 2008, Mixed brain pathologies in dementia: the BrainNet Europe consortium experience, Dement Geriatr Cogn Disord, 26, 343, 10.1159/000161560

Hyman, 2012, National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease, Alzheimers Dement, 8, 1, 10.1016/j.jalz.2011.10.007

Montine, 2012, National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach, Acta Neuropathol, 123, 1, 10.1007/s00401-011-0910-3

Burton, 2004, The relation of autopsy rate to physicians’ beliefs and recommendations regarding autopsy, Am J Med, 117, 255, 10.1016/j.amjmed.2004.01.028

Braskie, 2014, A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative, Biol Psychiatry, 75, 527, 10.1016/j.biopsych.2013.11.020

Nordberg, 2010, The use of PET in Alzheimer disease, Nat Rev Neurol, 6, 78, 10.1038/nrneurol.2009.217

Villemagne, 2015, Tau imaging: early progress and future directions, Lancet Neurol, 14, 114, 10.1016/S1474-4422(14)70252-2

Peskind, 2005, Safety and acceptability of the research lumbar puncture, Alzheimer Dis Assoc Disord, 19, 220, 10.1097/01.wad.0000194014.43575.fd

Blennow, 2010, Biomarkers in Alzheimer's disease drug development, Nat Med, 16, 1218, 10.1038/nm.2221

Kadir, 2011, Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease, Brain, 134, 301, 10.1093/brain/awq349

Forsberg, 2008, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol Aging, 29, 1456, 10.1016/j.neurobiolaging.2007.03.029

Mattsson, 2009, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, 302, 385, 10.1001/jama.2009.1064

Lerner, 2013, Amyloid imaging: the court of public opinion, Neurology, 81, 1108, 10.1212/WNL.0b013e3182a55fe3

Carrillo, 2013, Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium, Alzheimers Dement, 9, 137, 10.1016/j.jalz.2012.11.003

Leinenbach, 2014, Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid, Clin Chem, 60, 987, 10.1373/clinchem.2013.220392

Bittner, 2015, Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid, Alzheimers Dement

Villemagne, 2013, Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, Lancet Neurol, 12, 357, 10.1016/S1474-4422(13)70044-9

Ossenkoppele, 2015, Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis, JAMA, 313, 1939, 10.1001/jama.2015.4669

Jansen, 2015, Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis, JAMA, 313, 1924, 10.1001/jama.2015.4668

Gómez-Isla, 1996, Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease, J Neurosci, 16, 4491, 10.1523/JNEUROSCI.16-14-04491.1996

Sperling, 2011, Testing the right target and right drug at the right stage, Sci Transl Med, 3, 111cm33, 10.1126/scitranslmed.3002609

Galasko, 2013, Biomarkers for Alzheimer's disease in plasma, serum and blood—conceptual and practical problems, Alzheimers Res Ther, 5, 10, 10.1186/alzrt164

Mapstone, 2014, Plasma phospholipids identify antecedent memory impairment in older adults, Nat Med, 20, 415, 10.1038/nm.3466

Schedin-Weiss, 2014, The role of protein glycosylation in Alzheimer disease, FEBS J, 281, 46, 10.1111/febs.12590

Blennow, 2015, Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding, Nat Med, 21, 217, 10.1038/nm.3810

Carrillo, 2013, Research and standardization in Alzheimer's trials: reaching international consensus, Alzheimers Dement, 9, 160, 10.1016/j.jalz.2012.10.006

Frisoni, 2011, Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use, Alzheimers Dement, 7, 171, 10.1016/j.jalz.2010.06.007

Mattsson, 2012, Age and diagnostic performance of Alzheimer disease CSF biomarkers, Neurology, 78, 468, 10.1212/WNL.0b013e3182477eed

Wimo, 2014

2008

Wimo, 2014, Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria, J Intern Med, 275, 304, 10.1111/joim.12167

Bond, 2012, The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model, Health Technol Assess, 16, 1, 10.3310/hta16210

Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease, N Engl J Med, 366, 893, 10.1056/NEJMoa1106668

Brookmeyer, 2007, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement, 3, 186, 10.1016/j.jalz.2007.04.381

Howard, 2007, Donepezil for the treatment of agitation in Alzheimer's disease, N Engl J Med, 357, 1382, 10.1056/NEJMoa066583

Fox, 2012, Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial, PLoS ONE, 7, e35185, 10.1371/journal.pone.0035185

Rabins

Schneider, 2006, Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease, N Engl J Med, 355, 1525, 10.1056/NEJMoa061240

Porsteinsson, 2014, Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial, JAMA, 311, 682, 10.1001/jama.2014.93

Cohen-Mansfield, 2005, Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia, Alzheimer Dis Assoc Disord, 19, 37, 10.1097/01.wad.0000155066.39184.61

Suh, 2009, International price comparisons of Alzheimer's drugs: a way to close the affordability gap, Int Psychogeriatr, 21, 1116, 10.1017/S104161020999086X

Gauthier, 2015, Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials, Dement Geriatr Cogn Disord, 39, 332, 10.1159/000377672

Gilman, 2005, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, 64, 1553, 10.1212/01.WNL.0000159740.16984.3C

Orgogozo, 2003, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, 61, 46, 10.1212/01.WNL.0000073623.84147.A8

Coric, 2012, Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease, Arch Neurol, 69, 1430, 10.1001/archneurol.2012.2194

Doody, 2013, A phase 3 trial of semagacestat for treatment of Alzheimer's disease, N Engl J Med, 369, 341, 10.1056/NEJMoa1210951

De Strooper, 2014, Lessons from a failed γ-secretase Alzheimer trial, Cell, 159, 721, 10.1016/j.cell.2014.10.016

Yuzwa, 2014, Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice, Mol Neurodegener, 9, 42, 10.1186/1750-1326-9-42

Morris, 2014, Harmonized diagnostic criteria for Alzheimer's disease: recommendations, J Intern Med, 275, 204, 10.1111/joim.12199

Andersen, 2011, Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway, BMC Geriatr, 11, 58, 10.1186/1471-2318-11-58

Johnell, 2008, Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients, Drugs Aging, 25, 871, 10.2165/00002512-200825100-00006

Stuck, 1993, Comprehensive geriatric assessment: a meta-analysis of controlled trials, Lancet, 342, 1032, 10.1016/0140-6736(93)92884-V

Devons, 2002, Comprehensive geriatric assessment: making the most of the aging years, Curr Opin Clin Nutr Metab Care, 5, 19, 10.1097/00075197-200201000-00004

Bennett, 2013, Selected findings from the Religious Orders Study and Rush Memory and Aging Project, J Alzheimers Dis, 33, S397

James, 2012, Dementia from Alzheimer disease and mixed pathologies in the oldest old, JAMA, 307, 1798, 10.1001/jama.2012.3556

Haas, 2015, The European Medicines Agency's strategies to meet the challenges of Alzheimer disease, Nat Rev Drug Discov, 14, 221, 10.1038/nrd4585

2015

Papp, 2009, Immediate and delayed effects of cognitive interventions in healthy elderly: a review of current literature and future directions, Alzheimers Dement, 5, 50, 10.1016/j.jalz.2008.10.008

Willis, 2006, Long-term effects of cognitive training on everyday functional outcomes in older adults, JAMA, 296, 2805, 10.1001/jama.296.23.2805

Spector, 2012, Systematic review of neuropsychological outcomes in dementia from cognition-based psychological interventions, Dement Geriatr Cogn Disord, 34, 244, 10.1159/000343931

Owen, 2010, Putting brain training to the test, Nature, 465, 775, 10.1038/nature09042

Corbett, 2015, The effect of an online cognitive training package in healthy older adults: an online randomized controlled trial, J Am Med Dir Assoc, 16, 990, 10.1016/j.jamda.2015.06.014

Clare, 2010, Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy, Am J Geriatr Psychiatry, 18, 928, 10.1097/JGP.0b013e3181d5792a

Spector, 2006

Spector, 2003, Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial, Br J Psychiatry, 183, 248, 10.1192/bjp.183.3.248

Orrell, 2005, A pilot study examining the effectiveness of maintenance Cognitive Stimulation Therapy (MCST) for people with dementia, Int J Geriatr Psychiatry, 20, 446, 10.1002/gps.1304

Knapp, 2006, Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis, Br J Psychiatry, 188, 574, 10.1192/bjp.bp.105.010561

Spector, 2011, The impact of Cognitive Stimulation Therapy groups on people with dementia: views from participants, their carers and group facilitators, Aging Ment Health, 15, 945, 10.1080/13607863.2011.586622

Matsuda, 2010, Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease, Psychogeriatrics, 10, 167, 10.1111/j.1479-8301.2010.00335.x

Bahar-Fuchs, 2013, Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia, Cochrane Database Syst Rev, 6, CD003260

Gavett, 2011, The Cognitive Change in Women study (CCW): informant ratings of cognitive change but not self-ratings are associated with neuropsychological performance over 3 years, Alzheimer Dis Assoc Disord, 25, 305, 10.1097/WAD.0b013e31820d8652

Gifford, 2014, The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults, Alzheimers Dement, 10, 319, 10.1016/j.jalz.2013.02.007

Livingston, 2005, Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia, Am J Psychiatry, 162, 1996, 10.1176/appi.ajp.162.11.1996

Brodaty, 2012, Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia, Am J Psychiatry, 169, 946, 10.1176/appi.ajp.2012.11101529

Marin, 2003, Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease, Int Psychogeriatr, 15, 385, 10.1017/S1041610203009633

Wimo, 2004, Impact of donepezil treatment for Alzheimer's disease on caregiver time, Curr Med Res Opin, 20, 1221, 10.1185/030079902125004349

Knowles, 2006, Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes, Core Evid, 1, 195

Brodaty, 2003, Meta-analysis of psychosocial interventions for caregivers of people with dementia, J Am Geriatr Soc, 51, 657, 10.1034/j.1600-0579.2003.00210.x

Menne, 2014, Statewide implementation of “reducing disability in Alzheimer's disease”: impact on family caregiver outcomes, J Gerontol Soc Work, 57, 626, 10.1080/01634372.2013.870276

Corbett, 2012, Systematic review of services providing information and/or advice to people with dementia and/or their caregivers, Int J Geriatr Psychiatry, 27, 628, 10.1002/gps.2762

Geda, 2013, Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future, Alzheimers Dement, 9, 602, 10.1016/j.jalz.2012.12.001

Teri, 2003, Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial, JAMA, 290, 2015, 10.1001/jama.290.15.2015

Cohen-Mansfield, 2005, Nonpharmacological interventions for persons with dementia, Alzheimers Care Today, 6, 129

Ayalon, 2006, Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review, Arch Intern Med, 166, 2182, 10.1001/archinte.166.20.2182

Gitlin, 2010, Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention, J Am Geriatr Soc, 58, 1465, 10.1111/j.1532-5415.2010.02971.x

Testad, 2014, The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review, Int Psychogeriatr, 26, 1083, 10.1017/S1041610214000131

Logsdon, 2007, Evidence-based interventions to improve quality of life for individuals with dementia, Alzheimers Care Today, 8, 309

Cohen-Mansfield, 2007, Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention, J Gerontol A Biol Sci Med Sci, 62, 908, 10.1093/gerona/62.8.908

Fossey, 2014, The disconnect between evidence and practice: a systematic review of person-centred interventions and training manuals for care home staff working with people with dementia, Int J Geriatr Psychiatry, 29, 797, 10.1002/gps.4072

Ballard, 2015, Am J Psychiatry

Knapp

Molinuevo

Ballard, 2001, Quality of care in private sector and NHS facilities for people with dementia: cross sectional survey, BMJ, 323, 426, 10.1136/bmj.323.7310.426

Bergland, 2006, Thriving in nursing homes in Norway: contributing aspects described by residents, Int J Nurs Stud, 43, 681, 10.1016/j.ijnurstu.2005.09.006

Cooney, 2009, Resident perspectives of the determinants of quality of life in residential care in Ireland, J Adv Nurs, 65, 1029, 10.1111/j.1365-2648.2008.04960.x

Helgesen, 2010, ‘Patient participation’ in everyday activities in special care units for persons with dementia in Norwegian nursing homes, Int J Older People Nurs, 5, 169, 10.1111/j.1748-3743.2010.00223.x

Edvardsson, 2014, Everyday activities for people with dementia in residential aged care: associations with person-centredness and quality of life, Int J Older People Nurs, 9, 269, 10.1111/opn.12030

Funaki, 2005, Study on factors associated with changes in quality of life of demented elderly persons in group homes, Scand J Occup Ther, 12, 4, 10.1080/11038120510031725

Zimmerman, 2005, Dementia care and quality of life in assisted living and nursing homes, Gerontologist, 45, 133, 10.1093/geront/45.suppl_1.133

Kolanowski, 2006, Factors that relate to activity engagement in nursing home residents, Am J Alzheimers Dis Other Demen, 21, 15, 10.1177/153331750602100109

Murphy, 2007, Quality of life for older people living in long-stay settings in Ireland, J Clin Nurs, 16, 2167, 10.1111/j.1365-2702.2006.01865.x

Drageset, 2008, Differences in health-related quality of life between older nursing home residents without cognitive impairment and the general population of Norway, J Clin Nurs, 17, 1227, 10.1111/j.1365-2702.2007.02132.x

Kolanowski, 2011, A randomized clinical trial of theory-based activities for the behavioral symptoms of dementia in nursing home residents, J Am Geriatr Soc, 59, 1032, 10.1111/j.1532-5415.2011.03449.x

Cheng, 2012, Leisure activities alleviate depressive symptoms in nursing home residents with very mild or mild dementia, Am J Geriatr Psychiatry, 20, 904, 10.1097/JGP.0b013e3182423988

Zingmark, 2002, Promoting a good life among people with Alzheimer's disease, J Adv Nurs, 38, 50, 10.1046/j.1365-2648.2002.02145.x

Cohen-Mansfield, 2010, The impact of past and present preferences on stimulus engagement in nursing home residents with dementia, Aging Ment Health, 14, 67, 10.1080/13607860902845574

Cohen-Mansfield, 2010, The underlying meaning of stimuli: Impact on engagement of persons with dementia, Psychiatry Res, 177, 216, 10.1016/j.psychres.2009.02.010

Smit, 2014, Wellbeing-enhancing occupation and organizational and environmental contributors in long-term dementia care facilities: an explorative study, Int Psychogeriatr, 26, 69, 10.1017/S1041610213001397

Birks, 2009, Ginkgo biloba for cognitive impairment and dementia, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD003120.pub3

Scheltens, 2012, Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial, J Alzheimers Dis, 31, 225, 10.3233/JAD-2012-121189

Smith, 2010, Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial, PLoS ONE, 5, e12244, 10.1371/journal.pone.0012244

Dysken, 2014, Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial, JAMA, 311, 33, 10.1001/jama.2013.282834

Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med, 352, 2379, 10.1056/NEJMoa050151

Sano, 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study, N Engl J Med, 336, 1216, 10.1056/NEJM199704243361704

Quinn, 2010, Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial, JAMA, 304, 1903, 10.1001/jama.2010.1510

Freund-Levi, 2006, Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial, Arch Neurol, 63, 1402, 10.1001/archneur.63.10.1402

Henderson, 2009, Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial, Nutr Metab (Lond), 6, 31, 10.1186/1743-7075-6-31

Bjelakovic, 2008, Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD007176

Schürks, 2010, Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, BMJ, 341, c5702, 10.1136/bmj.c5702

Féart, 2009, Adherence to a Mediterranean diet, cognitive decline, and risk of dementia, JAMA, 302, 638, 10.1001/jama.2009.1146

Ballard, 2011, Alzheimer's disease, Lancet, 377, 1019, 10.1016/S0140-6736(10)61349-9

Valenzuela, 2008, Brain reserve and the prevention of dementia, Curr Opin Psychiatry, 21, 296, 10.1097/YCO.0b013e3282f97b1f

Lautenschlager, 2008, Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial, JAMA, 300, 1027, 10.1001/jama.300.9.1027

Nagamatsu, 2013, Physical activity improves verbal and spatial memory in older adults with probable mild cognitive impairment: a 6-month randomized controlled trial, J Aging Res, 2013, 861893, 10.1155/2013/861893

Baker, 2010, Effects of aerobic exercise on mild cognitive impairment: a controlled trial, Arch Neurol, 67, 71, 10.1001/archneurol.2009.307

McGough, 2011, Associations between physical performance and executive function in older adults with mild cognitive impairment: gait speed and the timed “up & go” test, Phys Ther, 91, 1198, 10.2522/ptj.20100372

Varela, 2012, Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: a randomized pilot study, Clin Rehabil, 26, 442, 10.1177/0269215511425835

Teixeira, 2012, Non-pharmacological interventions on cognitive functions in older people with mild cognitive impairment (MCI), Arch Gerontol Geriatr, 54, 175, 10.1016/j.archger.2011.02.014

Wimo, 2000, Assessment of informal services to demented people with the RUD instrument, Int J Geriatr Psychiatry, 15, 969, 10.1002/1099-1166(200010)15:10<969::AID-GPS272>3.0.CO;2-9

Malinowsky, 2014, An approach to facilitate healthcare professionals’ readiness to support technology use in everyday life for persons with dementia, Scand J Occup Ther, 21, 199, 10.3109/11038128.2013.847119

Jönsson, 2003

Helgesen, 2014, Patient participation in special care units for persons with dementia: A losing principle?, Nurs Ethics, 21, 108, 10.1177/0969733013486796

Wilberforce, 2011, Implementing consumer choice in long-term care: the impact of individual budgets on social care providers in England, Soc Policy Adm, 45, 593, 10.1111/j.1467-9515.2011.00788.x

Stolt, 2011, Privatization of social services: quality differences in Swedish elderly care, Soc Sci Med, 72, 560, 10.1016/j.socscimed.2010.11.012

Knapp, 1999, Private, voluntary or public? Comparative cost-effectiveness in community mental health care, Policy Polit, 27, 25, 10.1332/030557399782019589

Kendall, 2006, Social care and the nonprofit sector in the western developed world, 415

Wimo, 2010, The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia, J Nutr Health Aging, 14, 685, 10.1007/s12603-010-0316-2

van den Berg, 2006, Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving, Health Econ, 15, 447, 10.1002/hec.1075

Wimo, 1998, Evaluation of the resource utilization and caregiver time in anti-dementia drug trials—a quantitative battery, 465

Wimo, 2013, Application of Resource Utilization in Dementia (RUD) instrument in a global setting, Alzheimers Dement, 9, 429, 10.1016/j.jalz.2012.06.008

Beecham, 1992, Costing psychiatric interventions, 163

Clipp, 1995, Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease, Clin Pharmacol Ther, 58, 228, 10.1016/0009-9236(95)90201-5

Davis, 1997, The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease, Int J Geriatr Psychiatry, 12, 978, 10.1002/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-1

Sano, 2006, ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly, Alzheimer Dis Assoc Disord, 20, S191

Wimo, 2011, The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project, Int J Geriatr Psychiatry, 26, 825, 10.1002/gps.2610

Érsek, 2010, Costs of dementia in Hungary, J Nutr Health Aging, 14, 633, 10.1007/s12603-010-0309-1

Verbeek, 2012, A European study investigating patterns of transition from home care towards institutional dementia care: the protocol of a RightTimePlaceCare study, BMC Public Health, 12, 68, 10.1186/1471-2458-12-68

Olafsdóttir, 2001, Dementia in primary care: why the low detection rate?, Scand J Prim Health Care, 19, 194, 10.1080/028134301316982469

Edvardsson, 2008, Person-centred care of people with severe Alzheimer's disease: current status and ways forward, Lancet Neurol, 7, 362, 10.1016/S1474-4422(08)70063-2

Prince, 2013

Hill, 2002, Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare, Neurology, 58, 62, 10.1212/WNL.58.1.62

Wimo, 1993, Dementia day care and its effects on symptoms and institutionalization—a controlled Swedish study, Scand J Prim Health Care, 11, 117, 10.3109/02813439308994913

Wimo, 1994, Cost-effectiveness analysis of day care for patients with dementia disorders, Health Econ, 3, 395, 10.1002/hec.4730030607

Gaugler, 2003, Respite for dementia caregivers: the effects of adult day service use on caregiving hours and care demands, Int Psychogeriatr, 15, 37, 10.1017/S1041610203008743

Mittelman, 2006, Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease, Neurology, 67, 1592, 10.1212/01.wnl.0000242727.81172.91

Reilly, 2015, Case management approaches to home support for people with dementia, Cochrane Database Syst Rev, 1, CD008345

Challis, 2002, Care management, dementia care and specialist mental health services: an evaluation, Int J Geriatr Psychiatry, 17, 315, 10.1002/gps.595

Livingston, 2013, Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial, BMJ, 347, f6276, 10.1136/bmj.f6276

Knapp, 2013, Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial, BMJ, 347, f6342, 10.1136/bmj.f6342

Beauchamp, 2009

Forbes, 2013, Exercise programs for people with dementia, Cochrane Database Syst Rev, 12, CD006489

Vos, 2013, Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study, Lancet Neurol, 12, 957, 10.1016/S1474-4422(13)70194-7

Fox, 2013, Screening for dementia—is it a no brainer?, Int J Clin Pract, 67, 1076, 10.1111/ijcp.12239

Le Couteur, 2013, Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis, BMJ, 347, f5125, 10.1136/bmj.f5125

de Vugt, 2013, The impact of early dementia diagnosis and intervention on informal caregivers, Prog Neurobiol, 110, 54, 10.1016/j.pneurobio.2013.04.005

Derksen, 2006, Impact of diagnostic disclosure in dementia on patients and carers: qualitative case series analysis, Aging Ment Health, 10, 525, 10.1080/13607860600638024

Joosten-Weyn Banningh, 2008, Mild cognitive impairment: coping with an uncertain label, Int J Geriatr Psychiatry, 23, 148, 10.1002/gps.1855

Gauthier, 2013, Diagnosis and management of Alzheimer's disease: past, present and future ethical issues, Prog Neurobiol, 110, 102, 10.1016/j.pneurobio.2013.01.003

Gooblar, 2015, Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results, JAMA Neurol, 72, 1484, 10.1001/jamaneurol.2015.2875

Pepersack, 2008, Disclosing a diagnosis of Alzheimer's disease, Rev Med Brux, 29, 89

Ferrante di Ruffano, 2012, Assessing the value of diagnostic tests: a framework for designing and evaluating trials, BMJ, 344, e686, 10.1136/bmj.e686

Elwyn, 2013, Option Grids: shared decision making made easier, Patient Educ Couns, 90, 207, 10.1016/j.pec.2012.06.036

Boenink, 2011, Assessing the sociocultural impacts of emerging molecular technologies for the early diagnosis of Alzheimer's disease, Int J Alzheimers Dis, 2011, 184298

Buckles, 2003, Understanding of informed consent by demented individuals, Neurology, 61, 1662, 10.1212/01.WNL.0000098933.34804.FC

Karlawish, 2008, Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials, Am J Geriatr Psychiatry, 16, 568, 10.1097/JGP.0b013e318172b406

Kim, 2001, Assessing the competence of persons with Alzheimer's disease in providing informed consent for participation in research, Am J Psychiatry, 158, 712, 10.1176/appi.ajp.158.5.712

Forrest, 2007, Communicating genetic information in families—a review of guidelines and position papers, Eur J Hum Genet, 15, 612, 10.1038/sj.ejhg.5201822

Hoedemaekers, 2006, The complexities of ethical evaluation of genomics research, HEC Forum, 18, 18, 10.1007/s10730-006-7985-6

Menzel, 2013, Advance directives, dementia, and physician-assisted death, J Law Med Ethics, 41, 484, 10.1111/jlme.12057

Draper, 2010, Early dementia diagnosis and the risk of suicide and euthanasia, Alzheimers Dement, 6, 75, 10.1016/j.jalz.2009.04.1229

Boustani, 2008, Measuring primary care patients’ attitudes about dementia screening, Int J Geriatr Psychiatry, 23, 812, 10.1002/gps.1983

Finucane, 2007, Tube feeding in dementia: how incentives undermine health care quality and patient safety, J Am Med Dir Assoc, 8, 205, 10.1016/j.jamda.2007.01.007

Karlawish, 1999, American College of Physicians-American Society of Internal Medicine. A consensus-based approach to providing palliative care to patients who lack decision-making capacity, Ann Intern Med, 130, 835, 10.7326/0003-4819-130-10-199905180-00018

Andrés-Pretel, 2012, Seniors’ knowledge of and attitudes to advance directive documents, Gac Sanit, 26, 570, 10.1016/j.gaceta.2011.12.007

Brunner-La Rocca, 2012, End-of-life preferences of elderly patients with chronic heart failure, Eur Heart J, 33, 752, 10.1093/eurheartj/ehr404

Bravo, 2008, Assessing the effectiveness of interventions to promote advance directives among older adults: a systematic review and multi-level analysis, Soc Sci Med, 67, 1122, 10.1016/j.socscimed.2008.06.006

Hickman, 2011, The consistency between treatments provided to nursing facility residents and orders on the physician orders for life-sustaining treatment form, J Am Geriatr Soc, 59, 2091, 10.1111/j.1532-5415.2011.03656.x

Steptoe, 2015, Subjective wellbeing, health, and ageing, Lancet, 385, 640, 10.1016/S0140-6736(13)61489-0

Golden, 2009, Assessing advance directives in the homebound elderly, Am J Hosp Palliat Care, 26, 13, 10.1177/1049909108324359

Rurup, 2006, Frequency and determinants of advance directives concerning end-of-life care in The Netherlands, Soc Sci Med, 62, 1552, 10.1016/j.socscimed.2005.08.010

Groenewoud, 2000, A nationwide study of decisions to forego life-prolonging treatment in Dutch medical practice, Arch Intern Med, 160, 357, 10.1001/archinte.160.3.357

Molloy, 2000, Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial, JAMA, 283, 1437, 10.1001/jama.283.11.1437

Nicholas, 2011, Regional variation in the association between advance directives and end-of-life Medicare expenditures, JAMA, 306, 1447, 10.1001/jama.2011.1410

2015

Naisbitt, 1982, 123

Watson, 2014, EU pilot project promotes sharing of research data, BMJ, 348, g223, 10.1136/bmj.g223

Mello, 2013, Preparing for responsible sharing of clinical trial data, N Engl J Med, 369, 1651, 10.1056/NEJMhle1309073

Dixon, 2014, A dynamic model of patient consent to sharing of medical record data, BMJ, 348, g1294, 10.1136/bmj.g1294

Wilhelm, 2014, Approaches and costs for sharing clinical research data, JAMA, 311, 1201, 10.1001/jama.2014.850

Lutomski, 2013, The development of the Older Persons and Informal Caregivers Survey Minimum DataSet (TOPICS-MDS): a large-scale data sharing initiative, PLoS ONE, 8, e81673, 10.1371/journal.pone.0081673

Melis, 2011, Sharing of research data, Lancet, 378, 1995, 10.1016/S0140-6736(11)61870-9

Comas-Herrera, 2007, Cognitive impairment in older people: future demand for long-term care services and the associated costs, Int J Geriatr Psychiatry, 22, 1037, 10.1002/gps.1830

Scholar Hub - Công cụ hỗ trợ trích dẫn và phân tích khoa học Việt Nam

Về chúng tôi

Scholar Hub là công cụ hỗ trợ trích dẫn và phân tích các bài báo, công bố khoa học Việt Nam. Công cụ trợ giúp người nghiên cứu, tạp chí, đơn vị nghiên cứu tra cứu, phân tích và thống kê dữ liệu nghiên cứu khoa học tại Việt Nam và quốc tế.
ScholarHub KHÔNG đăng thông tin tổng hợp, KHÔNG đăng lại nội dung từ các trang báo chí Việt Nam hoặc trang thông tin điện tử khác tại Việt Nam.

Thông tin, cập nhật

Đăng ký Tạp chí tham gia vào Scholar Hub

Phản hồi ý kiến về Scholar Hub

Bài viết, nội dung cập nhật

Chủ đề khoa học

Website liên kết

Hệ thống CSDL Khoa học & Công nghệ

Phần mềm kiểm tra trùng lặp Kiểm Tra Tài Liệu

Phần mềm xuất bản tạp chí điện tử VOJS

Nền tảng trắc nghiệm và đề thi đa lĩnh vực LetQA